executive director of saen michael budkie made these reports public in a letter addressed to chancellor carol christ on wednesday.

now the country may face a fine of millions of euros after its dereliction was referred to the european court of justice (ecj), the guardian reports...

.
.
.
• eptinezumab is in phase iii trials. its maker plans to submit an application with the fda later this year. it is for chronic migraine prevention..